We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

58 hedge funds and large institutions have $65.6M invested in Lineage Cell Therapeutics in 2013 Q2 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

36.82% more ownership

Funds ownership: 0% → 36.82% (+37%)

75% less call options, than puts

Call options by funds: $196K | Put options by funds: $775K

Holders
58
Holders Change
+58
Holders Change %
–
% of All Funds
1.89%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
58
Increased
–
Reduced
–
Closed
–
Calls
$196K
Puts
$775K
Net Calls
-$579K
Net Calls Change
-$579K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AFG
26
Albion Financial Group
Utah
$91K +$91.6K +28,603 New
State Board of Administration of Florida Retirement System
27
State Board of Administration of Florida Retirement System
Florida
$90K +$90.4K +28,230 New
ProShare Advisors
28
ProShare Advisors
Maryland
$87K +$87.4K +27,281 New
Baillie Gifford & Co
29
Baillie Gifford & Co
United Kingdom
$82K +$82K +25,583 New
SCP
30
Seizert Capital Partners
Michigan
$80K +$79.8K +24,904 New
WJA
31
Williams Jones & Associates
New York
$79K +$79.4K +24,780 New
GC
32
Guggenheim Capital
Illinois
$76K +$75.9K +23,694 New
Swiss National Bank
33
Swiss National Bank
Switzerland
$73K +$73.4K +22,922 New
Goldman Sachs
34
Goldman Sachs
New York
$68K +$68.4K +21,354 New
Morgan Stanley
35
Morgan Stanley
New York
$57K +$56.6K +17,682 New
Group One Trading
36
Group One Trading
Illinois
$54K +$54.1K +16,894 New
Commonwealth Equity Services
37
Commonwealth Equity Services
Massachusetts
$54K +$54.6K +17,036 New
CS
38
Credit Suisse
Switzerland
$51K +$51.3K +16,017 New
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$46.2K +$46.3K +14,467 New
Barclays
40
Barclays
United Kingdom
$36K +$35.5K +11,074 New
Bank of America
41
Bank of America
North Carolina
$35K +$35.1K +10,969 New
PMFA
42
Plante Moran Financial Advisors
Michigan
$20K +$19.8K +6,195 New
TFA
43
Transamerica Financial Advisors
Florida
$17K +$16.1K +5,018 New
Fifth Third Bancorp
44
Fifth Third Bancorp
Ohio
$17K +$16.7K +5,204 New
Wells Fargo
45
Wells Fargo
California
$16K +$15.9K +4,956 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$10K +$10.1K +3,159 New
Ameriprise
47
Ameriprise
Minnesota
$9K +$9.14K +2,852 New
Teacher Retirement System of Texas
48
Teacher Retirement System of Texas
Texas
$8K +$7.61K +2,376 New
BlackRock
49
BlackRock
New York
$5K +$5.31K +1,658 New
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$3K +$3.17K +991 New
1
2
3

LCTX Hedge Fund Activity: Q2 2013 in Review

58 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2013, worth a combined $65.6M.

Buyers outnumbered sellers: 58 funds opened new LCTX positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.

  • 58 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $65.6M of Lineage Cell Therapeutics stock for Q2 2013.
  • 58 funds opened new Lineage Cell Therapeutics positions in Q2 2013 and 0 closed out, a net change of +58 holders.

Based on aggregated 13F filings for Q2 2013.